CPhI Worldwide: PCI Pharma shares expertise on serialisation and safe handling of potent molecules

Leading pharmaceutical provider PCI Pharma Services has provided expertise at CPhI Worldwide with two speaker slots at the ICSE Exhibitor Showcase.

Today David O’Connell, director of pharmaceutical development, PCI Pharma Services, spoke about the key elements for the safe handling and manufacturing of solid dose potent molecules. He gave advice on the complexities of safe processing of highly potent products and key considerations when choosing an outsourcing partner including key regulatory requirements.

On the topic of his presentation, O’Connell said: “The pharmaceutical landscape continues to evolve with R&D pipelines developing new chemical entities for a wide range of disease states. The market has seen a shift towards more specialist medicines such as oncological and neurological products, in turn leading to an increase in the number of potent compounds requiring expert management. With the complexities involved in the management of potent molecules and the regulatory requirements to ensure safe handling, it is imperative to use the right partner for successful development and manufacturing.”

On Wednesday, senior director of global serialisation, PCI Pharma Services Ian Parsonage, will cover key considerations, lessons learned and best practices for global serialisation strategy and implementation.

Parsonage commented: “With drug counterfeiting on the rise globally and regulatory deadlines fast approaching, the pharmaceutical supply chain will soon be at critical point to ensure patient safety. From drug manufacturers to distributors, supply chain partners need to make crucial decisions to upgrade production lines in compliance with traceability deadlines. I’m looking forward to sharing insights and best practices on how to execute a serialisation strategy at the event.”